Tag: https://www.bio.org/events/bio-international-convention
Fireside Chat on Life Science Industry in Maryland with Governor Moore and Rachel King, CEO of BIO Moderated by Dr. Bruce Jarrell, President of UMB. This event is intended to highlight the breadth and impact of Maryland’s bioscience community and to showcase the transformation of Maryland into a world-class center of biomedical innovation. source
BIO CEO Rachel King and Governor Wes Moore joined life sciences industry leaders at the University of Maryland (UM) BioPark … source
Rachel Diamant, Co-Founder of Emendo Biotherapeutics, talks about her company’s new generation of gene editing technology … source
Rep. Lisa McClain, Chair of the House Subcommittee on Health Care and Financial Services, and Joel White, President of the Council for Affordable Health Coverage, discuss the negative impact of the IRA on drug development, at the House Oversight Committee’s hearing, “The Inflation Reduction Act: A Year in Review” on September 14, 2023. source
A preview of this week’s House Oversight and Investigations Subcommittee Hearing on the Inflation Reduction Act: “At What Cost: Oversight of How the IRA’s Price Setting Scheme Means Fewer Cures for Patients.” Aiken Hackett, BIO’s VP of Federal Government Relations, previews the hearing and tells us what to expect. (September 20, 2023) The House hearing […]
John Crowley, CEO of Amicus Therapeutics and Vice Chair of the Board of the Biotechnology Innovation Organization (BIO), told Congress that drug price controls in the Inflation Reduction Act (IRA) harm the development of new drugs, as he testified before the House Energy & Commerce Oversight and Investigations Subcommittee on Sept. 20, 2023. Bio.News: https://bio.news/latest-news/bio-board-vice-chair-crowley-tells-congress-ira-reduces-access-to-innovative-drugs/ […]
We need to make progress against the next pandemic, Phyllis Arthur, Senior Vice President of Infectious Diseases & Emerging … source
Bipartisan agreement is rare these days, but members of both sides of the aisle agree on one thing: it’s time to reform the way … source
With the deadly threat of drug-resistant infections increasing daily, we desperately need actions to address the broken commercial marketplace for novel antimicrobials—including the PASTEUR Act, a novel pull incentive, and reforms to antimicrobial reimbursement—said a CEO speaking on behalf of the Biotechnology Innovation Organization (BIO) and the Antimicrobials Working Group (AWG) at a July 11 […]